|
Jul 3
|
Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports
|
|
Jul 3
|
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
|
|
Jun 16
|
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
|
|
Jun 2
|
Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal
|
|
Apr 25
|
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
|
|
Apr 25
|
Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
|
|
Apr 25
|
FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma
|
|
Apr 25
|
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
|
|
Apr 24
|
Akeso and Summit notch another Phase III win with their Keytruda competitor
|
|
Apr 23
|
Why Is Summit Therapeutics Stock Soaring On Wednesday?
|
|
Apr 23
|
Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy
|
|
Feb 14
|
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases
|
|
Feb 13
|
Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC
|
|
Jan 27
|
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
|